PMID- 31037974
OWN - NLM
STAT- MEDLINE
DCOM- 20200513
LR  - 20200513
IS  - 1532-7914 (Electronic)
IS  - 0163-5581 (Linking)
VI  - 71
IP  - 8
DP  - 2019
TI  - Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate 
      Cancer Cells.
PG  - 1299-1312
LID - 10.1080/01635581.2019.1601237 [doi]
AB  - Objective: Herein we, for the first time, investigated a potential synergistic 
      effect of nobiletin (NOB) and sorafenib (SOR) on PC-3 prostate cancer and HUVEC 
      control cell lines. Methods: In order to determine the cytotoxic and apoptotic 
      effects of the combination of NOB and SOR, WST-1, Annexin V, and cell cycle 
      analysis were performed. The potential molecular mechanism of apoptotic cell 
      death was assessed by Bax, Bcl-2, CCDN1, Rb1, and CDKN1A gene expression and 
      acridine orange (AO) and DAPI staining. Results: Our results indicated that NOB 
      and SOR combination had a significant inhibitory effect on the viability of PC-3 
      cells with less toxicity on HUVEC cells than SOR alone (P < 0.01). NOB and SOR 
      combination significantly caused much more apoptotic cell death and cell cycle 
      arrest at G0/G1 phase by up-regulation of Bax, Rb1, and CDKN1A levels in PC-3 
      cells (P < 0.01). Therefore, strong synergistic effects between NOB and SOR were 
      analyzed (CI < 1). Conclusion: NOB and SOR combination was more effective than 
      SOR and NOB alone and reduced the exposure time for SOR and NOB in PC-3 cells. 
      Combination strategy is a therapeutic potential to improve efficacy and reduce 
      side-effect of SOR for the treatment of metastatic prostate cancer cells.
FAU - Guney Eskiler, Gamze
AU  - Guney Eskiler G
AD  - Department of Medical Biology Faculty of Medicine, Sakarya University , Sakarya , 
      Turkey.
FAU - Deveci, Asuman Ozkan
AU  - Deveci AO
AUID- ORCID: 0000-0002-3248-4279
AD  - Department of Medical Biology Faculty of Medicine, Sakarya University , Sakarya , 
      Turkey.
FAU - Bilir, Cemil
AU  - Bilir C
AD  - Department of Medical Oncology Faculty of Medicine, Sakarya University , Sakarya 
      , Turkey.
FAU - Kaleli, Suleyman
AU  - Kaleli S
AD  - Department of Medical Biology Faculty of Medicine, Sakarya University , Sakarya , 
      Turkey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190430
PL  - United States
TA  - Nutr Cancer
JT  - Nutrition and cancer
JID - 7905040
RN  - 0 (Antioxidants)
RN  - 0 (Flavones)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - D65ILJ7WLY (nobiletin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Antioxidants/administration & dosage/pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Drug Synergism
MH  - Flavones/administration & dosage/*pharmacology
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis
MH  - PC-3 Cells
MH  - Prostatic Neoplasms/*drug therapy/pathology
MH  - Sorafenib/administration & dosage/*pharmacology
EDAT- 2019/05/01 06:00
MHDA- 2020/05/14 06:00
CRDT- 2019/05/01 06:00
PHST- 2019/05/01 06:00 [pubmed]
PHST- 2020/05/14 06:00 [medline]
PHST- 2019/05/01 06:00 [entrez]
AID - 10.1080/01635581.2019.1601237 [doi]
PST - ppublish
SO  - Nutr Cancer. 2019;71(8):1299-1312. doi: 10.1080/01635581.2019.1601237. Epub 2019 
      Apr 30.